LIXTE Biotechnology Holdings Provides Update on Recent Activities
Publishing of Findings in Recent Pre-Clinical Study for LIXTE’s Proprietary Compound, LB-100, in New Field of Cancer Biology, “Activation Lethality” […]
Lead Real Estate Co., Ltd. to Participate in Nasdaq Japan IR Event on June 20, 2024
TOKYO, May 20, 2024 (GLOBE NEWSWIRE) — Lead Real Estate Co., Ltd. (Nasdaq: LRE), a Japanese real estate developer of luxury residential […]
iPower’s SuperSuite Supply Chain Business Celebrates a Year of Transformative Growth
RANCHO CUCAMONGA, Calif., May 20, 2024 (GLOBE NEWSWIRE) — iPower Inc. (Nasdaq: IPW) (“iPower” or the “Company”), a tech and […]
Nanox to Report First Quarter and Financial Results on May 28, 2024
PETACH TIKVA, Israel, May 20, 2024 (GLOBE NEWSWIRE) — NANO-X IMAGING LTD (“Nanox” or the “Company,” Nasdaq: NNOX), an innovative […]
Lisata Therapeutics Receives Paediatric Investigation Plan Waiver from the European Medicines Agency for Certepetide in Pancreatic Cancer
Waiver confirms that paediatric studies of certepetide in pancreatic cancer are not needed Significant clinical trial burden and costs avoided […]
NETSOL Technologies Reports 14% Revenue Growth and EPS of $0.03 in Fiscal Third Quarter 2024
14% increase in Total Revenues to $15.5 million in 3Q ‘24 60% increase in 3Q ‘24 Services Revenues to $7.8 […]
eFFECTOR Therapeutics to Collaborate with the Dana-Farber Cancer Institute on an Investigator-Sponsored Phase 2 Clinical Trial Evaluating Zotatifin as Combination Treatment in ER+ Endometrial Cancer and in Low Grade Serous Ovarian Cancer
SOLANA BEACH, Calif. and REDWOOD CITY, Calif., May 20, 2024 (GLOBE NEWSWIRE) — eFFECTOR Therapeutics, Inc. (NASDAQ: EFTR), a leader […]
Gray Television Commences Cash Tender Offer for Its 5.875% Senior Notes Due 2026
ATLANTA, May 20, 2024 (GLOBE NEWSWIRE) — Gray Television, Inc. (“Gray,” the “Company,” “we,” or “our”) (NYSE: GTN) announced today […]
Gray Announces Private Offering of Senior Secured Notes
ATLANTA, May 20, 2024 (GLOBE NEWSWIRE) — Gray Television, Inc. (“Gray,” “we,” “us” or “our”) (NYSE: GTN) announced today that […]
NKGen Biotech’s SNK01 NK Cell Therapy Cleared to Start Phase 2 Clinical Trial in Alzheimer’s Disease
SNK01, a cryopreserved, autologous enhanced natural killer cell therapy, delivered in highest dose to date, demonstrates preliminary clinical benefit without […]
